Dosing & Uses
Dosage Forms & Strengths
injectable solution
- 6% (Dextran 70)
- 10% (Dextran 40)
Shock
No more than 20 mL/kg IV during first 24 hours; THEN 10 mL/kg/day
Same mL dosage for both 10% & 6%
10% Solution
- No more than 5 days
- First 500 mL infused rapidly, then slow infusion
Surgery (DVT/PE Prophylaxis)
10% Solution: 500-1000 mL (~10 mL/kg) on day of surgery; THEN 500 mL/day for 2-3 days; THEN 500 mL q2-3Days PRN up to 2 weeks
6% Solution: Not approved but used
Priming Fluid in Pump Oxygenators, Uterine Cavity Distention
Add 10-20 mL/kg (or 1-2 g/kg); not to exceed 20 mL/kg (2g/kg); dose varies with volume of pump oxygenator
Renal Impairment
Extreme caution
Hepatic Impairment
Extreme caution
Progenitor Cell Mobilization (Orphan)
Treatment to mobilze progenitor cells prior to stem cell transplantation
Orphan indication sponsor
- TikoMed AB; P.O. Box 81 (Karlsfaltsvagen 349); SE-263 03, Viken, Sweden
Pancreatic Islet Transplantation (Orphan)
LMW dextran sulfate (Ibsolvmir): Prevention of graft rejection during pancreatic islet transplantation
Orphan indication sponsor
- TikoMed AB; P.O. Box 81 (Karlsfaltsvagen 349); SE-263 03, Viken, Sweden
Dosage Forms & Strengths
Injectable Solution
- 6%
- 10%
10% Solution
Initial dose: 10 mL/kg IV infused rapidly, no more than 20 mL/kg/24 hours, THEN no more than 10 mL/kg/day, no more than 5 days
Shock
No more than 20 mL/kg IV during first 24 hours; THEN 10 mL/kg/day
Same mL dosage for both 10% & 6%
10% solution: No more than 5 days; First 500 mL infused rapidly, then slow infusion
Surgery (DVT/PE prophylaxis)
10% Solution: 500-1000 mL (~10 mL/kg) on day of surgery; THEN 500 mL/day for 2-3 days; THEN 500 mL q2-3Days PRN up to 2 weeks
6% Solution: Not approved but used
Priming fluid in pump oxygenators, uterine cavity distention
Add 10-20 mL/kg (or 1-2 g/kg); not to exceed 20 mL/kg (2g/kg); dose varies with volume of pump oxygenator
Adverse Effects
Frequency Not Defined
Congestive heart failure
Mild hypotension
Tightness of chest
Thrombocytopenia
Anaphylaxis
Injection site infection/phlebitis
Acute renal failure
Acidosis (if NaCl soln used)
Pulmonary edema
Wheezing
Warnings
Contraindications
Hypersensitivity to product or excipients
Marked hemostatic defects (eg, thrombocytopenia, hypofibrinogenemia) of all types including those caused by medications (eg, heparin, warfarin)
Marked cardiac decompensation
Renal disease with severe oliguria or anuria
Cautions
Not a substitute for blood or blood components
Administration may cause fluid overload; use with caution in patients at risk from overexpansion of blood volume (eg, very young, elderly patients, or those with heart failure)
Large volumes of dextran (doses >1000 mL) may cause reduction in hemoglobin concentration and excessive dilution of plasma proteins due to hemodilution; transient prolongation of bleeding time or increase in bleeding tendency may occur with large volumes; use caution to prevent a decrease in hematocrit <30%.
Severe and fatal anaphylactoid reactions reported; discontinue use immediately with signs of hypersensitivity and administer appropriate therapy.
Use with caution in heart failure patients; monitor closely for fluid overload
Use with caution in patients with active hemorrhage; may increase risk of more bleeding
Renal failure reported with use; use with caution in patients with renal impairment; fluid status including urine output should be monitored closely; excessive dosing may precipitate renal failure in patients with advanced renal disease; use in severe oliguria or anuria is contraindicated
Use with caution in patients with thrombocytopenia; doses >1000 mL may interfere with platelet function and transiently prolong bleeding time; observe for bleeding
Pregnancy & Lactation
Pregnancy Category: C
Lactation: not known if distributed into breast milk, avoid
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Branched polysaccharide volume expander through highly colloidal starch structure; lowers platelet & RBC adhesiveness
Pharmacokinetics
Elimination half-life: 40 min
Duration: 3-4hr (plasma expanding effects)
Distribution half-life: 12 min
Vd: 6.5 L
Metabolism: Minimally in tissues; liver, kidney, spleen
Excretion: urine 75%
Dialyzable: HD: No
Administration
IV Incompatibilities
Do not dilute or admix with other drugs
IV Administration
Infuse first 500 mL over 15-30 min, then slow infusion
Storage
Protect from freezing
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
